Amoy Diagnostics Co., Ltd. (300685.SZ)
CNY 20.82
(0.0%)
CNY 20.82
(0.0%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 1.03 Billion CNY | 23.35% |
| 2022 | 842.18 Million CNY | -8.16% |
| 2021 | 917.03 Million CNY | 25.9% |
| 2020 | 728.39 Million CNY | 25.94% |
| 2019 | 578.35 Million CNY | 31.73% |
| 2018 | 439.03 Million CNY | 32.89% |
| 2017 | 330.37 Million CNY | 30.59% |
| 2016 | 252.98 Million CNY | 43.03% |
| 2015 | 176.87 Million CNY | 65.6% |
| 2014 | 106.81 Million CNY | 43.61% |
| 2013 | 74.37 Million CNY | 94.98% |
| 2012 | 38.14 Million CNY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q3 | 304.95 Million CNY | -0.98% |
| 2024 Q1 | 232.49 Million CNY | -30.43% |
| 2024 Q2 | 307.96 Million CNY | 32.46% |
| 2023 Q2 | 263.54 Million CNY | 35.04% |
| 2023 Q4 | 334.2 Million CNY | 34.28% |
| 2023 FY | 1.03 Billion CNY | 23.35% |
| 2023 Q1 | 195.16 Million CNY | -19.66% |
| 2023 Q3 | 248.88 Million CNY | -5.56% |
| 2022 Q3 | 206.75 Million CNY | 10.88% |
| 2022 Q2 | 186.45 Million CNY | -9.51% |
| 2022 FY | 842.18 Million CNY | -8.16% |
| 2022 Q1 | 206.04 Million CNY | -24.05% |
| 2022 Q4 | 242.92 Million CNY | 17.49% |
| 2021 Q1 | 173.73 Million CNY | -28.91% |
| 2021 FY | 917.03 Million CNY | 25.9% |
| 2021 Q4 | 271.29 Million CNY | 9.93% |
| 2021 Q2 | 225.21 Million CNY | 29.63% |
| 2021 Q3 | 246.78 Million CNY | 9.57% |
| 2020 Q2 | 192.37 Million CNY | 112.21% |
| 2020 FY | 728.39 Million CNY | 25.94% |
| 2020 Q1 | 90.65 Million CNY | -45.35% |
| 2020 Q4 | 244.37 Million CNY | 21.58% |
| 2020 Q3 | 200.99 Million CNY | 4.48% |
| 2019 Q4 | 165.89 Million CNY | 13.2% |
| 2019 FY | 578.35 Million CNY | 31.73% |
| 2019 Q3 | 146.55 Million CNY | -0.09% |
| 2019 Q2 | 146.68 Million CNY | 23.03% |
| 2019 Q1 | 119.22 Million CNY | -7.25% |
| 2018 Q1 | 88.9 Million CNY | 1.33% |
| 2018 Q4 | 128.54 Million CNY | 19.03% |
| 2018 FY | 439.03 Million CNY | 32.89% |
| 2018 Q3 | 107.99 Million CNY | -4.93% |
| 2018 Q2 | 113.59 Million CNY | 27.77% |
| 2017 FY | 330.37 Million CNY | 30.59% |
| 2017 Q1 | 61.94 Million CNY | -13.94% |
| 2017 Q3 | 93.98 Million CNY | 8.39% |
| 2017 Q2 | 86.7 Million CNY | 39.96% |
| 2017 Q4 | 87.73 Million CNY | -6.65% |
| 2016 Q3 | 67.08 Million CNY | 17.78% |
| 2016 Q1 | 56.95 Million CNY | 0.0% |
| 2016 FY | 252.98 Million CNY | 43.03% |
| 2016 Q4 | 71.98 Million CNY | 7.31% |
| 2016 Q2 | 56.95 Million CNY | 0.0% |
| 2015 Q1 | 35.58 Million CNY | 0.0% |
| 2015 FY | 176.87 Million CNY | 65.6% |
| 2015 Q2 | 35.58 Million CNY | 0.0% |
| 2014 FY | 106.81 Million CNY | 43.61% |
| 2013 FY | 74.37 Million CNY | 94.98% |
| 2012 FY | 38.14 Million CNY | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Dian Diagnostics Group Co.,Ltd. | 13.4 Billion CNY | 92.252% |
| Hangzhou Tigermed Consulting Co., Ltd. | 7.38 Billion CNY | 85.931% |
| Dirui Industrial Co.,Ltd. | 1.36 Billion CNY | 23.801% |
| Beijing Strong Biotechnologies, Inc. | 1.74 Billion CNY | 40.353% |
| Medicalsystem Biotechnology Co., Ltd. | 1.88 Billion CNY | 44.915% |
| Maccura Biotechnology Co.Ltd | 2.89 Billion CNY | 64.126% |
| Guangzhou Wondfo Biotech Co.,Ltd | 2.76 Billion CNY | 62.428% |
| Guangdong Hybribio Biotech Co.,Ltd. | 1.1 Billion CNY | 5.941% |
| BGI Genomics Co., Ltd. | 4.34 Billion CNY | 76.117% |
| Shanghai Labway Clinical Laboratory Co., Ltd. | 1.67 Billion CNY | 37.957% |